Novo Nordisk A/S (NYSE: NVO), the Danish pharma that specializes in diabetes drugs, does not want to grow in China through M&A. It plans to continue its emphasis on developing its own innovative drugs. To that end, Novo Nordisk has previously announced investments in its Beijing R&D center and Tianjin manufacturing plant, while it is also working to increase diabetes education in China. "A few multinational companies made acquisitions (in China) to get entry into the generic medication and (over-the-counter) business,” said Ronald Frank Christie, senior vice-president of Novo Nordisk and president of Novo Nordisk (China) Pharmaceuticals Co., in a China Daily interview (see story). "Novo Nordisk is another kind of company. We want to concentrate on innovative new drugs."
